Bloom Burton analyst Prasath Pandurangan maintained a Hold rating on Trillium Therapeutics (NASDAQ:TRIL) on Friday, setting a price target of $18.5, which is approximately 4.88% above the present share price of $17.64.
Pandurangan expects Trillium Therapeutics to post earnings per share (EPS) of -$0.18 for the fourth quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Hold rating of shares in Trillium Therapeutics, with an average price target of $18.5.
The analysts price targets range from a high of $18.5 to a low of $18.5.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $10 thousand and a net profit of -$18.67 million. The company's market cap is $1.85 billion.
According to TipRanks.com, Bloom Burton analyst Prasath Pandurangan is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 0.4% and a 40.54% success rate.
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.